Ninety One (UK)
BIO icon

Ninety One (UK)’s Bio-Rad Laboratories Class A BIO Stock Holding History

Ninety One (UK)’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-387,310
Closed -$106M – 195
2024
Q2 		$106M Sell
387,310
-33,290
-8% -$9.68M 0.29% 65
2024
Q1 		$145M Buy
+420,600
New +$138M 0.41% 58

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ninety One (UK)'s BIO Position: Q3 2024 in Review

Ninety One (UK) sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2024, closing a stake of 387,310 shares — an estimated $106M sold.

Ninety One (UK) first reported a position in BIO in Q1 2024 and held it in 2 quarters. The position peaked at $145M in Q1 2024. 438 funds tracked by Wall St. Rank hold BIO as of Q3 2024.

  • Ninety One (UK) reported no remaining Bio-Rad Laboratories Class A position as of Q3 2024 after selling out during the quarter.
  • Ninety One (UK) sold 387,310 Bio-Rad Laboratories Class A shares in Q3 2024, an estimated $106M.
  • Ninety One (UK) first reported a position in Bio-Rad Laboratories Class A in Q1 2024 and held it in 2 quarters.
  • Ninety One (UK)'s Bio-Rad Laboratories Class A position peaked at $145M in Q1 2024.
  • 438 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2024.

Based on Ninety One (UK)'s 13F filing for Q3 2024, filed 12 Nov 2024.